LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Highly Sensitive Genetic Test for Glaucoma Developed

By LabMedica International staff writers
Posted on 28 Jul 2021
Print article
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)
In open-angle glaucoma, the angle in the eye where the iris meets the cornea is as wide and open as it should be, but the eye’s drainage canals become clogged over time, causing an increase in internal eye pressure and subsequent damage to the optic nerve.

Open-angle glaucoma is by far the most common type of glaucoma. It comes on so slowly and painlessly that it can go years without the sufferer knowing it, and by the time they are aware of the condition, it has probable done irreparable damage. Open-angle glaucoma usually happens to people over the age of 50.

Ophthalmologists at the Flinders University (Bedford Park, Australia) and their many colleagues compared polygenic and monogenic variants in risk of glaucoma. The team performed genetic testing on 2,507 Australian individuals with glaucoma, and 411,337 individuals with or without glaucoma in the UK.

The investigators reported that individuals at high polygenic risk, defined as those in the top 5% of an unselected population, had a glaucoma risk (odds ratio [OR], 2.77) comparable with the risk among individuals heterozygous for the MYOC p.Gln368Ter variant (OR 4.19), which is the most common single-gene variant known to cause primary open-angle glaucoma. High polygenic risk was more than six times more common than MYOC p.Gln368Ter heterozygosity in Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG) group (15.7% versus 2.6%) and more than 15 times more common in the general population (5.0% versus 0.32%).

Owen M. Siggs, MD, DPhil, an Associate Professor and first author of the study, said, “Early diagnosis of glaucoma can lead to vision-saving treatment, and genetic information can potentially give us an edge in making early diagnoses, and better treatment decisions.”

The authors concluded that monogenic and high polygenic risk were each associated with a more than 2.5-fold increased odds of developing glaucoma and an equivalent mean age at glaucoma diagnosis, with high polygenic risk more than 15 times more common in the general population. The study was published on July 15, 2021 in the journal JAMA Ophthalmology.

Related Links:
Flinders University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more